Stocks · News reference
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20
Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $18 to $20.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — NovoCure Ltd (NVCR)
Filed: 2026-10-01 AccNo: 0001645113-26-000071 Size: 163 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Novocure Reported Unauthorized Systems Access In Mid-August 2026, Exposing Internal Patient ID Numbers For Over 1,400 U.S. Records; No Medical Device Access Obtained, Operations, Systems Fully Functional
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.